
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Unveils Data Supporting Subcutaneous ‘1104 for Atopic Dermatitis Therapy
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide. Its subcutaneos formulation is currently being evaluated for the treatment of patients with atopic dermatitis.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Highlights Preclinical Data On Sublingual ‘1104 in Allergic Disease
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Validates Atopic Dermatitis as Target for Preclinical Candidate ‘1104
Details : 1104 is a first-in-class peptide currently being evaluated in early-stage clinical trials for the treatment of atopic dermatitis.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Data Validates Subcutaneous Administration of ‘1104 for Immune Disorders
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 24, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Receives Orphan Drug Designation for First-in-Class Peptide for EoE
Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ‘1104 (IRL201104), a first-in-class peptide that is involved in resetting the immune system, has recently advanced through two Phase 2a trials; one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 18, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers
Details : IRL201104 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 1104 (IRL201104) was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. 1104 for the treatment of patients with eosinophilic esophagitis (EoE) and allergic disease.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
